Physician profile
Edward Burris Eldred
NPI 1699975425
$1,400.52
in general payments reported to CMS, 2019-2025
20 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $134 · 2021: $401 · 2022: $260 · 2023: $83.03 · 2024: $141 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $381.72 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $182.94 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $173.20 | 2019-2025 | |
| Abbott Laboratories | $136.97 | 2021-2023 | Eterna |
| Amarin Pharma, INC. | $102.92 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $58.52 | 2019 | |
| Abbvie INC. | $53.56 | 2021-2024 | |
| Boston Scientific Corporation | $45.33 | 2024-2025 | Watchman Flx, Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $36.93 | 2021-2022 | |
| Edwards Lifesciences Corporation | $29.28 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ardelyx, INC. | $29.11 | 2025 | Ibsrela |
| Currax Pharmaceuticals LLC | $25.49 | 2020 | |
| Antares Pharma, INC. | $23.57 | 2025 | Xyosted |
| Corcept Therapeutics | $21.43 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.32 | 2025 | Gvoke Hypopen |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $19.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.38 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.45 | 2025 | Voquezna |
| Lilly USA, LLC | $14.25 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Eldred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.